US stock · Healthcare sector · Drug Manufacturers—Specialty & Generic
Company Logo

Catalent, Inc.

CTLTNYSE

72.74

USD
-1.99
(-2.66%)
After Hours Market
28.74P/E
16Forward P/E
1.43P/E to S&P500
13.086BMarket CAP
- -Div Yield
Upcoming Earnings
31 Oct-4 Nov
Shares Short
8/31/22
3.27M
Short % of Float
2.31%
Short % of Shares Outs.
1.82%
% Held by Insiders
0.34%
% Held by Institutions
99.65%
Beta
1.36
PEG Ratio
1.68
52w. high/low
140.56/72.69
Avg. Daily Volume
1.19M
Return %
Stock
S&P 500
1 year
(46.10)
(17.80)
3 years
55.66
23.21
5 years
89.05
45.98
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
30.18
19.30
34.41
23.63
32.24
18.92
43.39
25.51
47.87
29.23
58.38
29.29
120.48
31.04
142.64
97.86
128.26
73.89
Currency: USD
- -
- -
- -
- -
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
- -
- -
- -
- -
13.06
14.45
15.35
15.58
15.27
14.81
16.60
18.78
17.46
20.66
23.80
28.74
Earnings per share
- -
- -
- -
- -
(0.46)
(0.21)
(0.40)
0.14
1.77
0.89
0.88
0.64
0.92
1.47
3.48
2.99
FCF per share
- -
- -
- -
- -
0.11
(0.14)
0.13
0.48
0.26
0.13
1.28
1.51
0.21
(0.17)
(1.51)
(1.32)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.24
0.13
0.02
CAPEX per share
- -
- -
- -
- -
0.74
0.89
1.04
1.04
1.18
1.12
1.12
1.35
1.51
3.11
4.08
3.93
Book Value per sh.
- -
- -
- -
- -
- -
(2.99)
(3.50)
(3.16)
5.29
5.10
5.79
8.28
11.66
23.40
25.44
28.54
Comm.Shares outs.
- -
- -
- -
- -
117
117
117
117
120
125
125
131
144
150
168
168
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
172.3
16.2
28.0
39.5
64.5
51.5
51.9
34.0
34.0
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
9.5
0.8
1.3
1.7
2.6
2.1
1.4
1.1
1.7
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.3%
0.1%
0.0%
Revenue (m)
- -
- -
- -
- -
1,532
1,695
1,800
1,828
1,831
1,848
2,075
2,463
2,518
3,094
3,998
4,828
Operating margin
- -
- -
- -
- -
12.1%
11.7%
11.4%
13.2%
14.2%
11.8%
11.3%
11.0%
10.9%
12.7%
20.7%
15.7%
Depreciation (m)
- -
- -
- -
- -
116
130
152
143
141
141
147
190
229
254
289
378
Net profit (m)
- -
- -
- -
- -
(54)
(24)
(47)
16
212
112
110
84
132
221
585
503
Income tax rate
- -
- -
- -
- -
(438.9)%
2.7%
(100.8)%
73.4%
(86.8)%
23.3%
19.0%
45.0%
14.3%
15.2%
18.2%
14.2%
Net profit margin
- -
- -
- -
- -
(3.5)%
(1.4)%
(2.6)%
0.9%
11.6%
6.0%
5.3%
3.4%
5.2%
7.1%
14.6%
10.4%
Working capital (m)
- -
- -
- -
- -
- -
265
268
235
339
399
591
663
725
1,400
1,722
1,844
Long-term debt (m)
- -
- -
- -
- -
- -
2,640
2,657
2,685
1,864
1,833
2,055
2,649
2,883
2,945
3,166
4,171
Equity (m)
- -
- -
- -
- -
- -
(351)
(411)
(371)
634
636
724
1,087
1,682
3,505
4,274
4,795
ROIC
- -
- -
- -
- -
- -
5.7%
13.7%
2.3%
14.9%
6.6%
6.1%
3.7%
4.1%
4.8%
8.5%
6.5%
Return on capital
- -
- -
- -
- -
- -
5.1%
5.9%
7.4%
7.0%
7.6%
6.5%
5.8%
4.3%
5.0%
9.1%
6.8%
Return on equity
- -
- -
- -
- -
- -
7.0%
11.4%
(4.4)%
33.5%
17.5%
15.2%
7.7%
7.8%
6.3%
13.7%
10.5%
Plowback ratio
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
83.6%
96.2%
99.2%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
(0.4)%
(3,047.1)%
- -
- -
(140.3)%
(1,505.1)%
3,962.0%
23.7%
162.0%
Capital Structure
29 Aug · 2022 | Q4
All numbers in millions
Total liabilities
$ 5,712
Total assets
$ 10,507
Long-term debt
$ 4,171
Cash and equiv.
$ 449
Goodwill
$ 3,006
Retained earnings
$ 532
Common stock
180
Enterprise Value
$ 16,808
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
953
967
538
Receivables
919
1,243
1,051
Inventory
347
593
702
Other
74
58
121
Current assets
2,293
2,918
2,916
Acc. Payable
321
385
421
Debt due
73
91
31
Other
499
720
620
Current liabilities
893
1,196
1,072
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
20.76%
18.77%
12.08%
Cash flow
(12.65)%
152.08%
191.48%
Earnings
(14.02)%
69.04%
142.05%
Dividends
(81.82)%
- -
- -
Book value
12.19%
49.33%
(2.09)%
Insider Trading
Type
Shares
Date
Santiago Karen Murphy
Award
3,030
09/19/22
Santiago Karen Murphy
Award
1,681
09/19/22
Santiago Karen Murphy
Award
740
09/19/22
Flynn Karen
Award
245
09/15/22
Hopson Ricky
Sale
2,216
08/31/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
665
721
761
948
3,094
2021
846
911
1,053
1,188
3,998
2022
1,025
1,217
1,273
1,313
4,828
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
0.30
0.14
1.03
1.47
2021
0.49
0.53
1.38
1.09
3.48
2022
0.55
0.58
0.84
1.12
3.09
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.08
0.05
0.05
0.05
0.24
2021
0.05
0.03
0.03
0.03
0.13
2022
0.02
- -
- -
- -
0.02
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—Specialty & Generic
CEO:
Mr. John Chiminski
Full-time employees:
19,000
City:
Somerset
Address:
14 Schoolhouse Rd
IPO:
Jul 31, 2014
Website:
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Recent News